Trial · NCT01788306
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of Fatal Opioid Overdose | One year | Rate of fatal opioid overdose |
| Primary | Rate of Non-fatal Opioid Overdose | One year | Rate of non-fatal opioid overdose |
| Primary | Elapsed Time Until Opioid Overdose | Up to1064 days | Elapsed time until opioid overdose |
| Primary | Change in Overdose Risk (Change in Opioid Use - Heroin) | 3 months | Determine whether changes in behavior occur that increase or decrease risk of future overdose. Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use.(Data table includes proportions at 3 month follow-up.) |
| Primary | Change in Overdose Risk (Change in Opioid Use - Prescription-Type Opioids) | 3 months | Determine whether changes in behavior occur that increase or decrease risk of future overdose. Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use.(Data table includes proportions at 3 month follow-up.) |
| Primary | Change in Overdose Risk (Using Alone When Taking Opioids) | 3 months | Determine whether changes in behavior occur that increase or decrease risk of future overdose. Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use. (Data table includes means at 3 month follow-up.) |
| Primary | Change in Overdose Risk (Use of Sedatives When Taking Opioids) | 3 months | Determine whether changes in behavior occur that increase or decrease risk of future overdose. Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use. (Data table includes proportions at 3 month follow-up.) |
| Primary | Change in Overdose Risk (Use of Alcohol When Taking Opioids) | 3 months | Determine whether changes in behavior occur that increase or decrease risk of future overdose. Behaviors being measured include the amount of opioids taken, the use of opioids alone, use of opioids with alcohol or other drugs or medications, possessing naloxone, use of opioids in an environment that supports continued opioid use.(Data table includes proportions at 3 month follow-up.) |
| Secondary | Health Care Utilization (ED and Inpatient Admissions) | One year (annual rate) | Appropriate health care utilization (e.g. fewer emergency department visits and admissions to inpatient care) |
| Secondary | Change in HIV Risk Behaviors (Condom Use) | 3 months | Determine whether change occurs in the number of sexual risk behaviors (such as engaging in intercourse without a condom) and/or injection use behaviors (such as sharing syringes) that may increase the risk of contracting HIV.(Data table includes proportions at 3 month follow-up.) |
| Secondary | Change in HIV Risk Behaviors (Shared Syringes) | 3 months | Determine whether change occurs in the number of sexual risk behaviors (such as engaging in intercourse without a condom) and/or injection use behaviors (such as sharing syringes) that may increase the risk of contracting HIV. (Data table includes proportions at 3 month follow-up.) |
| Secondary | Change in Overdose Risk Behaviors and Perceptions (Take Home Naloxone) | 3 Months | Change in overdose response including naloxone availability and change in overdose risk perceptions. (Data table includes proportions at 3 month follow-up.) |
| Secondary | Change in Overdose Risk Behaviors and Perceptions (Likelihood of Overdose) | 3 Months | Change in overdose response including naloxone availability and change in overdose risk perceptions. (Data table includes proportions at 3 month follow-up.) |
| Secondary | Change in Overdose Risk Behaviors and Perceptions (Concerned About Overdose) | 3 Months | Change in overdose response including naloxone availability and change in overdose risk perceptions. (Data table includes proportions at 3 month follow-up.) |
| Secondary | Subgroup Analyses - Change in HIV Risk Behaviors (Condom Use) | 3 months | Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data table includes proportions at 3 month follow-up.) |
| Secondary | Subgroup Analyses - Change in HIV Risk Behaviors (Shared Syringes) | 3 months | Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data table includes proportions at 3 month follow-up.) |
| Secondary | Sub-group Analyses - Change in Overdose Risk (Change in Opioid Use - Heroin) | 3 months | Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data table includes proportions at 3 month follow-up.) |
| Secondary | Sub-group Analyses - Change in Overdose Risk (Change in Opioid Use - Prescription Type Opioids) | 3 months | Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data table includes proportions at 3 month follow-up.) |
| Secondary | Sub-group Analyses - Change in Overdose Risk (Using Alone When Taking Opioids) | 3 months | Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data table includes means at 3 month follow-up.) |
| Secondary | Subgroup Analyses- Change in Overdose Risk (Use of Sedatives When Taking Opioids) | 3 months | Sub-group analyses- primary and secondary outcomes will be examined by homelessness status at baseline.(Data table includes proportions at 3 month follow-up.) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01788306/registered